Effects of salvianolic acid B on liver mitochondria of rats with nonalcoholic steatohepatitis

World Journal of Gastroenterology

Volumn 21, Issue 35, 2015, Pages 10104-10112

  Wang, Ying Chun ^a,b   Kong, Wei Zong ^b   Jin, Qing Mei ^b   Chen, Juan ^b   Dong, Lei ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b DALIAN UNIVERSITY   (China)

Author keywords

Apoptosis; Liver; Mitochondria; Nonalcoholic steatohepatitis; Salvianolic acid B

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CASPASE 3; CHOLESTEROL; CYTOCHROME C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MALONALDEHYDE; MESSENGER RNA; MITOFUSIN 2; SALVIANOLIC ACID B; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; BENZOFURAN DERIVATIVE; BIOLOGICAL MARKER; CASP3 PROTEIN, RAT; MEMBRANE PROTEIN; MITOCHONDRIAL PROTEIN; MITOFUSIN 2 PROTEIN, RAT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOCHEMICAL ANALYSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIPID METABOLISM; LIPID PEROXIDATION; LIVER HISTOLOGY; LIVER MITOCHONDRION; LIVER PROTECTION; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MITOCHONDRION SWELLING; MORPHOLOGY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SPECTROPHOTOMETER; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; DISEASE MODEL; DRUG EFFECTS; GENETICS; LIPID DIET; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; SPRAGUE DAWLEY RAT; ULTRASTRUCTURE;

ANIMALS; APOPTOSIS; BENZOFURANS; BIOMARKERS; CASPASE 3; CYTOCHROMES C; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; LIPID PEROXIDATION; LIVER; MALE; MALONDIALDEHYDE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MEMBRANE PROTEINS; MITOCHONDRIA, LIVER; MITOCHONDRIAL PROTEINS; MITOCHONDRIAL SWELLING; NF-KAPPA B; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE;

EID: 84941892246     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i35.10104     Document Type: Article

References (33)

1. Jian-gao F. Guidelines for management of nonalcoholic fatty liver disease: an updated and revised edition. Zhonghua Ganzangbing Zazhi 2010; 18: 163-166 [PMID: 20698076]
2. Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 2009; 50: 204-210 [PMID: 19014878 DOI: 10.1016/j.jhep.2008.10.010]
3. Greenfield V, Cheung O, Sanyal AJ. Recent advances in nonalcholic fatty liver disease. Curr Opin Gastroenterol 2008; 24: 320-327 [PMID: 18408460 DOI: 10.1097/MOG.0b013e3282fbccf2]
4. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685 [PMID: 20427778 DOI: 10.1056/NEJMoa0907929]
5. Paradies G, Paradies V, Ruggiero FM, Petrosillo G. Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20: 14205-14218 [PMID: 25339807 DOI: 10.3748/wjg.v20.i39.14205]
6. Day CP, James OF. Steatohepatitis: a tale of two hits? Gastroenterology 1998; 114: 842-845 [PMID: 9547102]
7. van Hoek B. Non-alcoholic fatty liver disease: a brief review. Scand J Gastroenterol Suppl 2004; (241): 56-59 [PMID: 15696851]
8. Lee O, Bruce WR, Dong Q, Bruce J, Mehta R, O'Brien PJ. Fructose and carbonyl metabolites as endogenous toxins. Chem Biol Interact 2009; 178: 332-339 [PMID: 19000661 DOI: 10.1016/j.cbi.2008.10.011]
9. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321 [PMID: 15915461]
10. Flameng W, Andres J, Ferdinande P, Mattheussen M, Van Belle H. Mitochondrial function in myocardial stunning. J Mol Cell Cardiol 1991; 23: 1-11 [PMID: 2038066]
11. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408 [PMID: 11846609]
12. Mao YM. [Clinical diagnostic methods and evaluation of druginduced liver injury]. Zhonghua Ganzangbing Zazhi 2012; 20: 167-169 [PMID: 22629575]
13. Joe Y, Zheng M, Kim HJ, Kim S, Uddin MJ, Park C, Ryu do G, Kang SS, Ryoo S, Ryter SW, Chang KC, Chung HT. Salvianolic acid B exerts vasoprotective effects through the modulation of heme oxygenase-1 and arginase activities. J Pharmacol Exp Ther 2012; 341: 850-858 [PMID: 22442118 DOI: 10.1124/jpet.111.190736]
14. Ho JH, Hong CY. Salvianolic acids: small compounds with multiple mechanisms for cardiovascular protection. J Biomed Sci 2011; 18: 30 [PMID: 21569331 DOI: 10.1186/1423-0127-18-30]
15. Zhao CY, Liu XY, Shen C. [Molecular mechanisms of mitochondrial damage in the development of liver failure]. Zhonghua Ganzangbing Zazhi 2011; 19: 955-957 [PMID: 22553807]
16. Takaki A, Kawai D, Yamamoto K. Multiple hits, including oxidative stress, as pathogenesis and treatment target in nonalcoholic steatohepatitis (NASH). Int J Mol Sci 2013; 14: 20704-20728 [PMID: 24132155 DOI: 10.3390/ijms141020704]
17. Basaranoglu M, Basaranoglu G, Sentürk H. From fatty liver to fibrosis: a tale of second hit. World J Gastroenterol 2013; 19: 1158-1165 [PMID: 23483818 DOI: 10.3748/wjg.v19.i8.1158]
18. Sunny NE, Parks EJ, Browning JD, Burgess SC. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab 2011; 14: 804-810 [PMID: 22152305 DOI: 10.1016/j.cmet.2011.11.004]
19. Wei Y, Rector RS, Thyfault JP, Ibdah JA. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol 2008; 14: 193-199 [PMID: 18186554]
20. He J, Hu B, Shi X, Weidert ER, Lu P, Xu M, Huang M, Kelley EE, Xie W. Activation of the aryl hydrocarbon receptor sensitizes mice to nonalcoholic steatohepatitis by deactivating mitochondrial sirtuin deacetylase Sirt3. Mol Cell Biol 2013; 33: 2047-2055 [PMID: 23508103 DOI: 10.1128/MCB.01658-12]
21. Hallows WC, Yu W, Smith BC, Devries MK, Ellinger JJ, Someya S, Shortreed MR, Prolla T, Markley JL, Smith LM, Zhao S, Guan KL, Denu JM. Sirt3 promotes the urea cycle and fatty acid oxidation during dietary restriction. Mol Cell 2011; 41: 139-149 [PMID: 21255725 DOI: 10.1016/j.molcel.2011.01.002]
22. Bao J, Scott I, Lu Z, Pang L, Dimond CC, Gius D, Sack MN. SIRT3 is regulated by nutrient excess and modulates hepatic susceptibility to lipotoxicity. Free Radic Biol Med 2010; 49: 1230-1237 [PMID: 20647045 DOI: 10.1016/j.freeradbiomed.2010.07.009]
23. Gan KX, Wang C, Chen JH, Zhu CJ, Song GY. Mitofusin-2 ameliorates high-fat diet-induced insulin resistance in liver of rats. World J Gastroenterol 2013; 19: 1572-1581 [PMID: 23538485 DOI: 10.3748/wjg.v19.i10.1572]
24. Chen XL, Lei YR. [Effects of hydrodynamics-mediated RNAi on Mfn2 expression, blood sugar and fat levels in mice]. Zhonghua Gan Zang Bing Za Zhi 2010; 18: 778-782 [PMID: 21059297 DOI: 10.3760/cma.j.issn.1007-3418.2010.10.013]
25. Lan CH, Fang DC, Fan LL, He ZG, Chen DF, Liu CY, Shi HT. [The role of mitochondrial damages in Helicobacter pylori-induced apoptosis of gastric cancer cells]. Zhonghua Neike Zazhi 2005; 44: 748-750 [PMID: 16255882]
26. Ngo JK, Pomatto LC, Davies KJ. Upregulation of the mitochondrial Lon Protease allows adaptation to acute oxidative stress but dysregulation is associated with chronic stress, disease, and aging. Redox Biol 2013; 1: 258-264 [PMID: 24024159 DOI: 10.1016/j.redox.2013.01.015]
27. Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol 2008; 14: 6395-6400 [PMID: 19009658]
28. Martel C, Esposti DD, Bouchet A, Brenner C, Lemoine A. Nonalcoholic steatohepatitis: new insights from OMICS studies. Curr Pharm Biotechnol 2012; 13: 726-735 [PMID: 22122481]
29. Pessayre D, Fromenty B, Berson A, Robin MA, Lettéron P, Moreau R, Mansouri A. Central role of mitochondria in druginduced liver injury. Drug Metab Rev 2012; 44: 34-87 [PMID: 21892896 DOI: 10.3109/03602532.2011.604086]
30. Apraiz A, Boyano MD, Asumendi A. Cell-centric view of apoptosis and apoptotic cell death-inducing antitumoral strategies. Cancers (Basel) 2011; 3: 1042-1080 [PMID: 24212653 DOI: 10.3390/cancers3011042]
31. Akar FG, O'Rourke B. Mitochondria are sources of metabolic sink and arrhythmias. Pharmacol Ther 2011; 131: 287-294 [PMID: 21513732 DOI: 10.1016/j.pharmthera.2011.04.005]
32. Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 2012; 52: 59-69 [PMID: 22064361 DOI: 10.1016/j.freeradbiomed. 2011.10.003]
33. Balmer ML, Dufour JF. [Non-alcoholic steatohepatitis-from NAFLD to MAFLD]. Ther Umsch 2011; 68: 183-188 [PMID: 21452138 DOI: 10.1024/0040-5930/a000148]